Circular Genomics recently moved its headquarters to Lilly Gateway Labs, aiming to enhance its Alzheimer's disease ...

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

Eli Lilly's much-anticipated drug for diabetes and obesity, that competes with Ozempic globally, is now in India. Here's what ...

Eli Lilly and Co. is in negotiations with several states and plans to announce the locations of four new manufacturing plants ...

Eli Lilly launches diabetes and obesity drug Mounjaro in India, offering innovative treatment for metabolic health management ...

Eli Lilly & Co.’s stock rose 1.6% Wednesday, after the drug company announced plans to expand its U.S. manufacturing sites by adding four more locations this year, along with 13,000 high-wage jobs.

The four sites would create more than 3,000 jobs for scientists, engineers, operations personnel, lab technicians and other highly skilled workers, according to Eli Lilly. They also would create ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Eli Lilly has reduced the prices of certain Zepbound vials and introduced higher-dose options, making the weight-loss drug ...

Eli Lilly has launched its blockbuster diabetes and weight-loss drug Mounjaro in India following approval from the country’s ...

Eli Lilly has said it is prepared to invest £279 ... creation of a UK biotech hub – provisionally called Lilly Gateway Labs (LGL) – to support early-stage life sciences businesses working ...

Eli Lilly (LLY) stock in focus as the company launches its weight loss therapy Mounjaro in India, beating its rival Novo Nordisk (NVO). Read more here.